A citation-based method for searching scientific literature

Yunjuan Zhao, Lin Yang, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2014
Times Cited: 39







List of co-cited articles
251 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
73
30

Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
Bertram Bengsch, Bianca Seigel, Tobias Flecken, Julia Wolanski, Hubert E Blum, Robert Thimme. J Immunol 2012
101
25

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
86
25

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
20

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Odd Erik Johansen, Bernhard O Boehm, Valdemar Grill, Peter A Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle. Diabetes Care 2014
41
17

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
17

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
37
16

Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes.
Tímea Varga, Anikó Somogyi, Gábor Barna, Barna Wichmann, Géza Nagy, Károly Rácz, László Selmeci, Gábor Firneisz. Pathol Oncol Res 2011
39
15

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck, Gordon S Howarth, Catherine A Abbott. Trends Pharmacol Sci 2009
180
15

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
12

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
12


Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.
Kei Ohnuma, Nam H Dang, Chikao Morimoto. Trends Immunol 2008
163
12


Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
C Klemann, L Wagner, M Stephan, S von Hörsten. Clin Exp Immunol 2016
171
12

Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Marcelo Maia Pinheiro, Caroline Lais Stoppa, Claudete Justina Valduga, Cristina Eunice Okuyama, Renata Gorjão, Regina Mara Silva Pereira, Susana Nogueira Diniz. Eur J Pharm Sci 2017
39
12

Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Margareth Afonso Torres. Endocrinol Diabetes Metab Case Rep 2016
17
29

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda,[...]. Diabetes Ther 2017
25
20

Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).
R Buzzetti, P Pozzilli, R Frederich, N Iqbal, B Hirshberg. Diabetes Metab Res Rev 2016
31
16

Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study.
Zhiguang Zhou, Yufei Xiang, Linong Ji, Weiping Jia, Guang Ning, Gan Huang, Lin Yang, Jian Lin, Zhenqi Liu, William A Hagopian,[...]. Diabetes 2013
135
12

Dipeptidyl peptidase in autoimmune pathophysiology.
Kei Ohnuma, Osamu Hosono, Nam H Dang, Chikao Morimoto. Adv Clin Chem 2011
50
10


Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
271
10

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
68
10


The structure and function of CD26 in the T-cell immune response.
C Morimoto, S F Schlossman. Immunol Rev 1998
331
10

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Seoyoung C Kim, Sebastian Schneeweiss, Robert J Glynn, Michael Doherty, Allison B Goldfine, Daniel H Solomon. Ann Rheum Dis 2015
54
10

Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus.
Atsushi Iwabuchi, Tomohiro Kamoda, Makoto Saito, Hiroki Nozue, Isho Izumi, Takeki Hirano, Ryo Sumazaki. J Pediatr Endocrinol Metab 2013
19
21

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
Yoshimasa Aso, Maiko Fukushima, Masaaki Sagara, Teruo Jojima, Toshie Iijima, Kunihiro Suzuki, Atsushi Momobayashi, Kikuo Kasai, Toshihiko Inukai. Diabetes Res Clin Pract 2015
23
17

Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus.
Narayanan Kandasamy, Graham Lennox, Anand K Annamalai, Gerald Maguire, Amanda I Adler. Endocr Pract 2012
9
44

Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults.
E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis, K Kotsa. Endocrinol Diabetes Metab Case Rep 2016
21
19

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin.
Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble, Constantin Polychronakos. Endocrinol Diabetes Metab Case Rep 2014
14
28

The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
33
12

Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.
Zhifang Yang, Zhiguang Zhou, Xia Li, Gan Huang, Jian Lin. Diabetes Res Clin Pract 2009
38
10

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
7


Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Gian Paolo Fadini, Angelo Avogaro. Vascul Pharmacol 2011
159
7





Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.
Shuling Yan, Didier Marguet, Jörg Dobers, Werner Reutter, Hua Fan. Eur J Immunol 2003
85
7

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
617
7

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
173
7

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Tatsuhiko Saito, Kei Ohnuma, Hiroshi Suzuki, Nam H Dang, Ryou Hatano, Hiroki Ninomiya, Chikao Morimoto. Diabetes Res Clin Pract 2013
21
14

A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data.
Hua Yu, Jianxin Chen, Xue Xu, Yan Li, Huihui Zhao, Yupeng Fang, Xiuxiu Li, Wei Zhou, Wei Wang, Yonghua Wang. PLoS One 2012
201
7

A novel chemometric method for the prediction of human oral bioavailability.
Xue Xu, Wuxia Zhang, Chao Huang, Yan Li, Hua Yu, Yonghua Wang, Jinyou Duan, Yang Ling. Int J Mol Sci 2012
286
7

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Jae Min Cho, Hye Won Jang, Hwanju Cheon, Yeon Taek Jeong, Do-Hoon Kim, Yu-Mi Lim, Song-Hyen Choi, Eun-Kyoung Yang, Chang-Yell Shin, Moon Ho Son,[...]. Diabetes Res Clin Pract 2011
40
7

CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.
Kei Ohnuma, Tadanori Yamochi, Masahiko Uchiyama, Kunika Nishibashi, Noritada Yoshikawa, Noriaki Shimizu, Satoshi Iwata, Hirotoshi Tanaka, Nam H Dang, Chikao Morimoto. Proc Natl Acad Sci U S A 2004
87
7

The multifunctional or moonlighting protein CD26/DPPIV.
Emil Boonacker, Cornelis J F Van Noorden. Eur J Cell Biol 2003
233
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.